Good appointment imho.
This is lining up HBV preclinical I believe.
I still think HCV is a waste of time, except for the fact that there's plenty of coinfected to deal with. BIT225 has proven almost nothing against HCV and the market is very much taken already. DYOR.
HBV represents a bigger target than HIV imho.
Ann: Appointment of a Director and Appendix 3X, page-25
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.18M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.8¢ | $1.335K | 34.62K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1131315 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 330372 | 2 |
View Market Depth
| Last trade - 15.04pm 09/07/2024 (20 minute delay) ? |
| BIT (ASX) Chart |